Skip to content

Study on the efficacy and mechanism of ARB drugs in patients with coronary microcirculation disorders after PCI surgery for coronary heart disease

Study on the efficacy and mechanism of ARB drugs in patients with coronary microcirculation disorders after PCI surgery for coronary heart disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071431
Enrollment
Unknown
Registered
2023-05-15
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease PCI surgery with coronary microcirculation disorders

Interventions

Experimental group:Conventional drug therapy + Azilsartan 20mg qd
Control group:Conventional drug therapy

Sponsors

Shaanxi Provincial People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-75 years old, gender is not limited, (2) Coronary heart disease was clearly diagnosed and PCI was successfully performed to open the subepicardial coronary artery, and the residual stenosis diameter of each branch of coronary artery was < 50%. (3) Oral medication (aspirin 100mg qd, clopidogrel 75mg qd, atorvastatin calcium 20mg qd) 1 month after PCI surgery), there are still angina, exertional chest tightness, shortness of breath or other atypical myocardial ischemia-related symptoms, (4) CAG review showed that the diameter of the epicardial coronary artery stenosis of each branch was <50%, (5) Sign the informed consent form and voluntarily participate in this study, (6) The temperature-pressure guide wire determination IMR was successfully completed.

Exclusion criteria

Exclusion criteria: (1) Suffering from chronic cardiac insufficiency, diabetes, kidney disease, acute coronary syndrome, (2) Diseases with upper respiratory tract infection, tumors and other diseases that have a greater impact on inflammation-related indicators, (3) Severe liver insufficiency (ALT or AST>200U/l), renal insufficiency (GFR<60ml/min), (4) Cardiac ultrasound showed that the left ventricular ejection fraction was < 50%, (5) Severe arrhythmias that may cause hemodynamic instability, (6) There are contraindications to intravenous injection of adenosine triphosphate or allergies to it, (7) Poor medication compliance, unable to take medication on time, and return to the clinic on time, (8) Combined with malignant tumors and other diseases, life expectancy < 1 year.

Design outcomes

Primary

MeasureTime frame
Coronary flow reserve fraction;SIRT1;NLPR3;IL-8;

Countries

China

Contacts

Public ContactCheng gong

Shaanxi Provincial People’s Hospital

xianchenggong@163.com+86 186 2952 9996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026